Colfosceril palmitate: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== Colfosceril Palmitate == | |||
== | [[File:Colfosceril_Palmitate.png|thumb|right|Chemical structure of Colfosceril Palmitate]] | ||
'''Colfosceril palmitate''' is a synthetic [[lung surfactant]] used primarily in the treatment of [[neonatal respiratory distress syndrome]] (NRDS) in premature infants. It is a type of [[phospholipid]] that mimics the natural surfactant produced by the lungs, which is essential for reducing surface tension in the alveoli and preventing lung collapse. | |||
== Mechanism of Action == | |||
Colfosceril palmitate | Colfosceril palmitate works by replacing or supplementing the deficient or dysfunctional surfactant in the lungs of premature infants. The primary component of natural surfactant is [[dipalmitoylphosphatidylcholine]] (DPPC), which is also the main component of colfosceril palmitate. By reducing the surface tension at the air-liquid interface within the alveoli, colfosceril palmitate helps to stabilize the alveoli, improve lung compliance, and enhance gas exchange. | ||
== | == Clinical Use == | ||
Colfosceril palmitate is administered intratracheally, meaning it is delivered directly into the trachea of the infant. This allows the surfactant to reach the alveoli quickly and exert its effects. It is typically used in the treatment of NRDS, a condition that occurs in premature infants due to insufficient production of natural surfactant. The administration of colfosceril palmitate can significantly reduce the severity of respiratory distress and improve survival rates in affected infants. | |||
== Side | == Side Effects == | ||
While colfosceril palmitate is generally well-tolerated, some potential side effects may occur. These can include [[bradycardia]], [[hypotension]], [[oxygen desaturation]], and [[pulmonary hemorrhage]]. These side effects are usually transient and can be managed with appropriate medical intervention. | |||
== | == History == | ||
The development of synthetic surfactants like colfosceril palmitate marked a significant advancement in the treatment of neonatal respiratory distress syndrome. Before the availability of surfactant therapy, NRDS was a major cause of morbidity and mortality in premature infants. The introduction of colfosceril palmitate and other surfactant preparations has dramatically improved outcomes for these patients. | |||
== | == Related Pages == | ||
* [[Neonatal respiratory distress syndrome]] | * [[Neonatal respiratory distress syndrome]] | ||
* [[Surfactant]] | * [[Surfactant replacement therapy]] | ||
* [[ | * [[Dipalmitoylphosphatidylcholine]] | ||
* [[Premature birth]] | |||
[[Category: | [[Category:Pulmonology]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Neonatology]] | |||
Latest revision as of 05:32, 16 February 2025
Colfosceril Palmitate[edit]
Colfosceril palmitate is a synthetic lung surfactant used primarily in the treatment of neonatal respiratory distress syndrome (NRDS) in premature infants. It is a type of phospholipid that mimics the natural surfactant produced by the lungs, which is essential for reducing surface tension in the alveoli and preventing lung collapse.
Mechanism of Action[edit]
Colfosceril palmitate works by replacing or supplementing the deficient or dysfunctional surfactant in the lungs of premature infants. The primary component of natural surfactant is dipalmitoylphosphatidylcholine (DPPC), which is also the main component of colfosceril palmitate. By reducing the surface tension at the air-liquid interface within the alveoli, colfosceril palmitate helps to stabilize the alveoli, improve lung compliance, and enhance gas exchange.
Clinical Use[edit]
Colfosceril palmitate is administered intratracheally, meaning it is delivered directly into the trachea of the infant. This allows the surfactant to reach the alveoli quickly and exert its effects. It is typically used in the treatment of NRDS, a condition that occurs in premature infants due to insufficient production of natural surfactant. The administration of colfosceril palmitate can significantly reduce the severity of respiratory distress and improve survival rates in affected infants.
Side Effects[edit]
While colfosceril palmitate is generally well-tolerated, some potential side effects may occur. These can include bradycardia, hypotension, oxygen desaturation, and pulmonary hemorrhage. These side effects are usually transient and can be managed with appropriate medical intervention.
History[edit]
The development of synthetic surfactants like colfosceril palmitate marked a significant advancement in the treatment of neonatal respiratory distress syndrome. Before the availability of surfactant therapy, NRDS was a major cause of morbidity and mortality in premature infants. The introduction of colfosceril palmitate and other surfactant preparations has dramatically improved outcomes for these patients.
